ABSTRACT
Traumatic injuries to the anterior maxilla usually lead to loss of teeth by means of avulsion or extraction due to fracture. Rehabilitation of such a clinical scenario is complex as it involves various anatomic and esthetic challenges. Single-piece basal implants have been widely used in the rehabilitation of resorbed ridges because they gain adequate anchorage from the basal cortical bone, allowing immediate temporization or loading. However, the use of basal implants in the anterior esthetic zone is not much documented. This case report with a five-year follow-up period describes the rehabilitation of lost teeth in the anterior esthetic zone of the anterior maxilla caused due to trauma following a train accident using single-piece axial basal implants with immediate temporization.
ABSTRACT
Objective: Vaginal agenesis or atresia in females suffering from MRKH syndrome is more common and management involves both surgical and non-surgical approaches. Use of prefabricated stents to maintain the patency of the canal may not fit appropriately during the initial surgical phase and are not economical. This case report discusses a series of modifications in a custom-made vaginal dilator to improve the retention for expansion after surgical management of MRKH syndrome. Case report: A 28-year-old female diagnosed with MRKH syndrome with characteristic Mullerian agenesis was referred for customised vaginal stent. Customised surgical stent was fabricated with loops for orientation and retention, which was later modified into interim expansion and passive stent. Conclusion: The customisation of the vaginal stent, provision of a retentive loop that positioned the stent in the proper orientation, and gradual increase in the size of the stent, ensured dilatation in a patient with vaginal agenesis.
ABSTRACT
STATEMENT OF PROBLEM: Dental implants are susceptible to early failure when placed in patients diagnosed with type 2 diabetes mellitus. The osteoinductive potential of insulin-like growth factor-1 (IGF-1) has been widely investigated in animals with type 2 diabetes mellitus, but studies investigating the osteoinductive potential of IGF-1 around dental implants in patients diagnosed with type 2 diabetes mellitus are lacking. PURPOSE: This randomized controlled trial was conducted to assess the osteogenic efficacy of poly(lactide-co-glycolide)- (PLGA) encapsulated IGF-1 microspheres around dental implants placed in patients diagnosed with type 2 diabetes mellitus. MATERIAL AND METHODS: A split-mouth, randomized controlled trial was conducted in 10 participants diagnosed with type 2 diabetes mellitus and with bilaterally missing mandibular posterior teeth. The 20 sites were randomly allotted to receive the PLGA encapsulated IGF-1 or placebo microspheres followed by the placement of Ø3.8×11-mm implants. Osteoblastic activity was quantitatively assessed with bone scintigraphy scanning on the thirtieth, sixtieth, and 90th day after implant placement. The Shapiro-Wilks test was used to analyze the normality of data, followed by the independent t test to compare the experimental and placebo groups. Intragroup comparison was performed by using repeated-measures ANOVA and the post hoc Bonferroni test (α=.05). RESULTS: Statistical analysis revealed that the mean osteoblastic activity was higher in the experimental group which received the PLGA-encapsulated IGF-1 than in the placebo group at the 30th, 60th, and 90th day after implant placement (P≤.001). CONCLUSIONS: This randomized controlled trial indicated that the PLGA-encapsulated sustained release of IGF-1 microspheres enhanced the process of osseointegration in patients diagnosed with type 2 diabetes mellitus until the 90th day after implant placement.
